Replies to post #222169 on Biotech Values

[rfj1862]

AZN’s oncology pipeline is weighted toward “targeted” agents rather than I-O, so I’m not sure “exciting” is the most apt description. Imfinzi is distant fourth in the PD(L)-1 category.

I would use the term "innovative" -- they are addressing a broad range of novel targets, most of which aren't me-toos.

Immunooncology is crowded to say the least.